Equities analysts expect Selecta Biosciences, Inc. (NASDAQ:SELB) to report sales of $20.58 million for the current quarter, Zacks reports. Two analysts have made estimates for Selecta Biosciences’ earnings, with estimates ranging from $20.00 million to $21.15 million. Selecta Biosciences posted sales of $11.95 million during the same quarter last year, which suggests a positive year-over-year growth rate of 72.2%. The firm is scheduled to issue its next quarterly earnings results on Thursday, March 10th.
On average, analysts expect that Selecta Biosciences will report full-year sales of $63.11 million for the current fiscal year, with estimates ranging from $51.08 million to $75.14 million. For the next fiscal year, analysts forecast that the company will post sales of $73.98 million, with estimates ranging from $55.00 million to $92.96 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Selecta Biosciences.
Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings results on Monday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.09). During the same period in the prior year, the business posted ($0.09) EPS.
NASDAQ:SELB remained flat at $$3.18 during midday trading on Thursday. 659,427 shares of the company traded hands, compared to its average volume of 1,245,667. Selecta Biosciences has a one year low of $2.67 and a one year high of $5.70. The company’s fifty day moving average price is $4.04. The company has a market capitalization of $370.94 million, a P/E ratio of -6.12 and a beta of 1.01.
In other news, CEO Carsten Brunn sold 15,313 shares of the stock in a transaction that occurred on Wednesday, October 13th. The stock was sold at an average price of $4.39, for a total transaction of $67,224.07. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 24.00% of the company’s stock.
Several large investors have recently made changes to their positions in SELB. Legal & General Group Plc lifted its position in shares of Selecta Biosciences by 39.0% during the 2nd quarter. Legal & General Group Plc now owns 9,512 shares of the company’s stock valued at $40,000 after buying an additional 2,668 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in Selecta Biosciences in the 2nd quarter valued at $45,000. Axiom Investment Management LLC purchased a new position in Selecta Biosciences in the 1st quarter valued at $45,000. Natixis purchased a new position in Selecta Biosciences in the 3rd quarter valued at $47,000. Finally, Squarepoint Ops LLC purchased a new position in Selecta Biosciences in the 2nd quarter valued at $49,000. Hedge funds and other institutional investors own 70.05% of the company’s stock.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.
Recommended Story: How to interpret the current ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.